INCREASED SERUM LEVEL OF PEPTIDYL ARGININE DEIMINASE TYPE 4 IN VARIOUS MOLECULAR BIOLOGICAL SUBTYPES OF BREAST CANCER

Cover Page

Cite item

Abstract

Level of enzyme peptidyl arginine deiminase type 4 (PAD-4) was determined in serum samples collected from 98 females with primary breast cancer within January, 2017 – April, 2018 divided into 5 groups according to immunohistochemistry data: group 1 – luminal A cancer, 2 – luminal B Her-2 negative, 3 – luminal B Her-2 positive, 4 – non-luminal Her-2 positive, 5 – triple negative cancer. Samples were collected prior to the onset of any anti-cancer treatment, and in 41 cases – 15-24 days after performing radical surgery. Control samples were obtained from 20 healthy females. Serum PAD-4 level was measured with Human PAD-4 ELISA Kit (Wuhan Fine Biotech Co., Ltd, China) on automatic analyzer ADALTIS Personal LAB (Adaltis S.r.l., Italy). Statistical analysis was performed by using software IBM SPSS Statistics 19. Mean serum PAD-4 level before treatment was 9.0 ng/ml that did not change after surgery. However, mean PAD-4 level for healthy females was 1.5 ng/ml (0.0-2.0) ng/ml that significantly differed from cancer group (Mann–Whitney U test, U = 38.500, p<0.001). in contrast PAD-4 level in various cancer groups was: group 1 – 11.05 ng/ml, group 2 – 11.9 ng/ml, group 3 – 10.8 ng/ml, group 4 – 7.99 ng/ml, group 5 – 9.9 ng/ml. Thus, level of serum PAD-4 was higher in groups with more favorable luminal cancer, but further research is needed to make definitive conclusions.

About the authors

O. S. Tereshin

Chelyabinsk Regional Cinical Center of Oncology and Nuclear Medicine

Author for correspondence.
Email: olegter@mail.ru

Tereshin Oleg S. , PhD (Medicine), Head, Breast Oncology Department

454087, Chelyabinsk, Blyukher str., 42. Phone: 7 (902) 899-19-39

Russian Federation

A. B. Semenova

Chelyabinsk Regional Cinical Center of Oncology and Nuclear Medicine

Email: fake@neicon.ru
Semenova A.B., PhD, MD (Medicine), Head, Laboratory Department Russian Federation

A. V. Vazhenin

Chelyabinsk Regional Cinical Center of Oncology and Nuclear Medicine

Email: fake@neicon.ru
Vazhenin A.V., PhD, MD (Medicine), Professor, Full Member, Russian Academy of Sciences, Chief Physician Russian Federation

I. I. Dolgushin

South Ural State Medical University

Email: fake@neicon.ru
Dolgushin I.I., PhD, MD (Medicine), Professor, Corresponding Member, Russian Academy of Sciences, Director Russian Federation

K. V. Nikushkina

South Ural State Medical University

Email: fake@neicon.ru
Nikushkina K.V., PhD (Medicine), Leading Research Associate Russian Federation

T. I. Nikonova

South Ural State Medical University

Email: fake@neicon.ru
Nikonova T.I., Junior Research Associate Russian Federation

References

  1. Berger-Achituv S., Brinkmann V., Abed U.A., Kühn L.I., Ben-Ezra J., Elhasid R., Zychlinsky A.A proposed role for neutrophil extracellular traps in cancer immunoediting. Front. Immunol., 2013, Vol. 4, pp. 1-5.
  2. Chang X., Fang K. PADI4 and tumorogenesis. Cancer Cell Int., 2010, Vol. 10, no. 7, pp. 1-6.
  3. Chang X., Han J., Pang L., Zhao Y., Yang Y., Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer, 2009, Vol. 9, pp. 1-11.
  4. Christophorou M.A., Castelo-Branco G., Halley-Stott R.P., Oliveira C.S., Loos R., Radzisheuskaya A., Mowen K.A., Bertone P., Silva J.C., Zernicka-Goetz M., Nielsen M.L., Gurdon J.B., Kouzarides T. Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature, 2014, Vol. 507, no. 7490, pp. 104-108.
  5. Guo Q., Fast W. Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J. Biol. Chem., 2011, Vol. 286, pp. 17069-17078.
  6. Hensen S.M., Pruijn G.J. Methods for the detection of peptidylarginine deiminase (PAD) activity and protein citrullination. Mol. Cell Proteomics., 2014, Vol. 13, pp. 388-396.
  7. Nauseef W.M., Borregaard N. Neutrophils at work. Nat. Immunol., 2014, Vol. 15, pp. 602-611.
  8. Rogers G.E., Simmonds D.H. Content of citrulline and other aminoacids in a protein of hair follicles. Nature, 1958, Vol. 182, pp. 186-187.
  9. Saiki M., Watase M., Matsubayashi H., Hidaka Y. Recognition of the N-terminal histone H2A and H3 peptides by peptidylarginine deiminase IV. Protein Pept. Lett., 2009, Vol. 16, pp. 1012-1016.
  10. Stadler S.C., Vincent C.T., Fedorov V.D., Patsialou A., Cherrington B.D., Wakshlag J.J., Mohanan S., Zee B.M., Zhang X., Garcia B.A., Condeelis J.S., Brown A.M., Coonrod S.A., Allis C.D. Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc. Natl. Acad. Sci. USA, 2013, Vol. 110, pp. 11851-11856.
  11. Tohme S., Yazdani H.O., Al-Khafaji A.B., Chidi A.P., Loughran P., Mowen K., Wang Y., Simmons R.L., Huang H., Tsung A. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res., 2016, Vol. 76, pp. 1367-1380.
  12. Wang S., Wang Y. Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim. Biophys. Acta., 2013, Vol. 1829, pp. 1126-1135.
  13. Witalison E., Thompson P., Hofseth L. Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation. Curr. Drug. Targets., 2015, Vol. 16, pp. 700- 710.
  14. Zawrotniak M., Rapala-Kozik M. Neutrophil extracellular traps (NETs) – formation and implications. Acta. Biochim. Pol., 2013, Vol. 60, pp. 277-284.

Copyright (c) 2020 Tereshin O.S., Semenova A.B., Vazhenin A.V., Dolgushin I.I., Nikushkina K.V., Nikonova T.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies